200
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer

, , , , &
Pages 69-78 | Published online: 04 May 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Sherko Kümmel, Christian Jackisch, Volkmar Müller, Andreas Schneeweiss, Sandra Klawitter & Michael P Lux. (2018) Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?. Cancer Management and Research 10, pages 5423-5431.
Read now

Articles from other publishers (2)

Elena A. Pudova, George S. Krasnov, Anastasiya A. Kobelyatskaya, Maria V. Savvateeva, Maria S. Fedorova, Vladislav S. Pavlov, Kirill M. Nyushko, Andrey D. Kaprin, Boris Y. Alekseev, Dmitry Y. Trofimov, Gennady T. Sukhikh, Anastasiya V. Snezhkina & Anna V. Kudryavtseva. (2021) Gene Expression Changes and Associated Pathways Involved in the Progression of Prostate Cancer Advanced Stages. Frontiers in Genetics 11.
Crossref
Daniel Stellato, Marroon Thabane, Caitlin Eichten & Thomas E. Delea. (2021) Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer. Current Oncology 28:1, pages 491-508.
Crossref